Piritrexim

吡曲克辛

Report date: 2023/04/21 17:47:03
NME

Base Information

Drug NamePiritrexim
Drug Alias NameBW-301UNSC-351521BW 301U301U74
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDihydrofolate reductase inhibitors
TargetsDihydrofolate reductase
Therapy Area/IndicationsUrinary Bladder NeoplasmsUrethral NeoplasmsCarcinoma, Renal Cell +[4
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Africa
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsUrinary Bladder NeoplasmsUrethral NeoplasmsCarcinoma, Renal Cell +[4

Other Information

ATC CodeN/A
Related LinksN/A